Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Diagnosis

Follow up FDG PET/CT for Recurrence Detection and Survival Outcome Prediction in Patients with non-Hodgkin lymphoma

Mehdi Taghipour, Charles Marcus, Pratyusha Nunna and Rathan Subramaniam
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 599;
Mehdi Taghipour
1Radiology, The Johns Hopkins Medical Institutions, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Marcus
1Radiology, The Johns Hopkins Medical Institutions, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pratyusha Nunna
1Radiology, The Johns Hopkins Medical Institutions, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rathan Subramaniam
1Radiology, The Johns Hopkins Medical Institutions, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

599

Objectives This study is designed to evaluate the value of follow up PET/CT in the detection of recurrence as well as determining its prognostic value in patients with non-Hodgkin lymphoma (NHL).

Methods All patients diagnosed with NHL who had at least one follow up PET/CT six months after the completion of their treatment were included. There were 204 eligible NHL patients and 560 eligible PET/CT scans. The accuracy of PET/CT scans was established with histopathology or six months clinical follow up as reference standard. The change in management was recorded after each follow up PET/CT scan in comparison to the management plan prior to the study. Cox regression model was established for clinical covariates and imaging results. Overall survival was evaluated using Kaplan-Meier plots with a Log-rank test.

Results The sensitivity, specificity, PPV, NPV, and accuracy of FDG-PET/CT in detecting recurrent lymphoma were 95.1%, 90.5%, 84.5%, 97.1%, 92.1% respectively. Among 560 scans, 388 (69.3%) scans were done routinely and 172 (30.7%) scans were done due to clinical suspicion. Follow up scan results suggested disease in 22.2% routine scan and ruled out suspected disease in 17.4% scans with prior clinical suspicion. The management of NHL patients was changed after 17% of follow up scans. New treatment modalities were started for 15.7% of patients, and the treatment modality was changed or stopped after 1.6% of scans. The management of NHL patients was not changed after 74.8% scans (53.6% no treatment to no treatment and 21.2% continue the same treatment). A total of 157 (77%) patients survived and 47 (23%) patients had died during the median follow up period of 16.5 months. On multivariate Cox regression analysis, age (p < 0.001) was the only significant factor predicting overall survival.

Conclusions Follow up PET/CT scans added value to clinical assessment and management of NHL patients and had excellent accuracy in recurrence detection.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Follow up FDG PET/CT for Recurrence Detection and Survival Outcome Prediction in Patients with non-Hodgkin lymphoma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Follow up FDG PET/CT for Recurrence Detection and Survival Outcome Prediction in Patients with non-Hodgkin lymphoma
Mehdi Taghipour, Charles Marcus, Pratyusha Nunna, Rathan Subramaniam
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 599;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Follow up FDG PET/CT for Recurrence Detection and Survival Outcome Prediction in Patients with non-Hodgkin lymphoma
Mehdi Taghipour, Charles Marcus, Pratyusha Nunna, Rathan Subramaniam
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 599;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Diagnosis

  • Application of 18F-FDG PET/CT in primary thyroid lymphoma
  • Effect of respiratory gated positron emission tomography on clinical staging and management of lung cancer
  • 18F-FDG PET/CT imaging features of pancreatic solid pseudopapillary tumor
Show more Oncology: Clinical Diagnosis

Leukemia/Lymphoma/Myeloma I

  • Definition of diffuse micronodular spleen infestation (DMSI) in FDG-PET of pediatric patients with Hodgkin’s lymphoma (HL)
  • The impact of the Point-spread-function (PSF) reconstruction on the response assessment in the Interim F18-FDG-PET (iPET) in Hodgkin lymphoma (HL).
  • Comparison of interim PET (iPET) response to relapse vs. first-line treatment in children with classical Hodgkin lymphoma (HL) - contribution to the development of response criteria for relapsed HL
Show more Leukemia/Lymphoma/Myeloma I

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire